Chemoprophylaxis for HIV Prevention in Men.

Trial Profile

Chemoprophylaxis for HIV Prevention in Men.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
  • Indications Herpes simplex virus type 2 infections; HIV infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms iPrEX
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Aug 2016 Results of this and other four studies published in the Antimicrobial Agents and Chemotherapy (2016).
    • 22 Aug 2016 According to a Gilead Sciences media release, the European Commission has granted marketing authorisation in the European Union (EU) for once daily Truvada (emtricitabine / tenofovir disoproxil) for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually-acquired human immunodeficiency virus type 1 (HIV-1) infection in adults at high risk based on data from this and PartnerPrEP (CTP 700028654) trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top